Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Related Keywords

Connecticut ,United States ,New Haven ,Samer Zeidan ,Daiichi Sankyo ,States Cerner Enviza ,Boehringer Ingelheim Incyte ,Genentech ,Novartis ,Myeloid Malignancies At Yale Cancer Center ,Early Therapeutics Research ,Amgen ,Pfizer ,Clinical Research Team For Leukemias ,Clinical Research Team ,Myeloid Malignancies ,Yale Cancer Center ,End Results ,United States Cerner Enviza ,Charlson Comorbidity Index ,Medicare Advantage ,Seattle Genetics ,Lox Oncology ,Shattuck Labs ,Lymphoma Myeloma ,Oral Decitabine Cedazuridine ,Parenteral Hypomethylating Agents ,Intravenous Subcutaneous Hypomethylating Agents ,Patients With Myelodysplastic Syndrome ,Bbs ,